Clinical Trial Search

Primary: Incidence Rate of Composite Outcome (Stroke, Systemic Embolism, Myocardial Infarction, Life-threatening Bleeding Events and Vascular Death) - Phase II — 2.06 Events per…

Primary: Sleep Quality Evaluation — 4.63; 11.75 score on a scale

Primary: Number of Participants With Treatment Response During Medication Phase at Stage 1 — 10; 18; 284; 91 Participants

Primary: Percentage of Participants With a Hb Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy — 89.5; 78.0…

Primary: Percentage of Participants With Previous Occurence of Cardiovascular Comorbidities — 20.4; 21.6; 26.4 Percentage of participants — p=<0.001

Primary: Changes in the Quality of Life of Patients Suffering From Acute or Chronic Hemorrhoids Within 1 Month After Presenting to a Doctor (Visit V0 vs Visit3) — 16.5; 11.1…

Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants

Primary: DB Period: Mean Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Treatment Period After the First Dose of…

Primary: Difference in the Distribution of Fecal Microbiota in Each Participant

Primary: Change in Exhaled NO Before and After Treatment — 39.5 parts per billion — p=<=0.05

Primary: Percentage of Participants With Maximum Pain Level Decreased by ≥ 2 Points at 2 Months After Radiofrequency Ablation (RFA) — 83.6 percentage of participants

Primary: Cardiac Output — -3.7; -1.4; 1 millilitres

Primary: Disease-Free Survival — 40.9; 41.4 percentage of participants

Primary: Medication Adherence — 91.2; 85.5 percentage of days covered

Primary: Concentration of Ixazomib in Tumor Tissue — 7.88; 2.03; 4.17; 2.70 ng/g